cdr132l
Nucleic acidexperimental
Clinical trial activity
5 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Jun 21, 2019 (NCT04045405)
Timeline
Indications
Mechanism of action
- MicroRNA 132INHIBITOR
MicroRNA 132 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06979375 | Phase 2 | Jun 30, 2025 | Novo Nordisk |
| NCT06979362 | Phase 2 | Jun 27, 2025 | Novo Nordisk |
| NCT05953831 | Phase 2 | Dec 31, 2023 | Cardior Pharmaceuticals GmbH |
| NCT05350969 | Phase 2 | Jun 27, 2022 | Cardior Pharmaceuticals GmbH, Gottfried Wilhelm Leibniz Universität Hannover |
| NCT04045405 | Phase 1 | Jun 21, 2019 | Cardior Pharmaceuticals GmbH, Richmond Pharmacology |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cardior Pharmaceuticals GmbH | For profit | 3 | 3 | 2 | 2019 |
| Novo Nordisk | For profit | 2 | 2 | 1 | 2025 |
| Gottfried Wilhelm Leibniz Universität Hannover | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Richmond Pharmacology | For profit | 1 | 0 | 1 | 2019 |
4 organizations
Page 1 / 1